Photo from wikipedia
The CSCO and ASCO guidelines in 2021 recommend chemotherapy for stage III–IVA (8th edition of AJCC staging) nasopharyngeal carcinoma (NPC). Actually, patients with stage T3–4N0M0 are often excluded from various… Click to show full abstract
The CSCO and ASCO guidelines in 2021 recommend chemotherapy for stage III–IVA (8th edition of AJCC staging) nasopharyngeal carcinoma (NPC). Actually, patients with stage T3–4N0M0 are often excluded from various clinical trials of the locoregionally advanced NPC, and the survival benefit of chemotherapy in such patients has always been controversial. This study aims to explore the benefit of chemotherapy in patients with locoregionally advanced NPC, especially those with negative lymph nodes.
Keywords:
nasopharyngeal carcinoma;
advanced nasopharyngeal;
locoregionally advanced;
chemotherapy locoregionally;
chemotherapy
Journal Title: Cancer Medicine
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer Medicine
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!